JPH0432061B2 - - Google Patents

Info

Publication number
JPH0432061B2
JPH0432061B2 JP58131085A JP13108583A JPH0432061B2 JP H0432061 B2 JPH0432061 B2 JP H0432061B2 JP 58131085 A JP58131085 A JP 58131085A JP 13108583 A JP13108583 A JP 13108583A JP H0432061 B2 JPH0432061 B2 JP H0432061B2
Authority
JP
Japan
Prior art keywords
group
carbon atoms
chloro
bromo
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58131085A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5933250A (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10531878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0432061(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of JPS5933250A publication Critical patent/JPS5933250A/ja
Publication of JPH0432061B2 publication Critical patent/JPH0432061B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
JP58131085A 1982-07-23 1983-07-20 アシルアニリド、その製法及び抗アンドロゲン作用を有する医薬又は獣医薬組成物 Granted JPS5933250A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8221421 1982-07-23
GB8221421 1982-07-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP1230574A Division JPH02131462A (ja) 1982-07-23 1989-09-07 アシルアニリド、その製法及び抗アンドロゲン作用を有する医薬又は獣医薬組成物

Publications (2)

Publication Number Publication Date
JPS5933250A JPS5933250A (ja) 1984-02-23
JPH0432061B2 true JPH0432061B2 (en, 2012) 1992-05-28

Family

ID=10531878

Family Applications (2)

Application Number Title Priority Date Filing Date
JP58131085A Granted JPS5933250A (ja) 1982-07-23 1983-07-20 アシルアニリド、その製法及び抗アンドロゲン作用を有する医薬又は獣医薬組成物
JP1230574A Pending JPH02131462A (ja) 1982-07-23 1989-09-07 アシルアニリド、その製法及び抗アンドロゲン作用を有する医薬又は獣医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP1230574A Pending JPH02131462A (ja) 1982-07-23 1989-09-07 アシルアニリド、その製法及び抗アンドロゲン作用を有する医薬又は獣医薬組成物

Country Status (23)

Country Link
US (1) US4636505A (en, 2012)
EP (1) EP0100172B1 (en, 2012)
JP (2) JPS5933250A (en, 2012)
AT (1) ATE28864T1 (en, 2012)
AU (1) AU556328B2 (en, 2012)
CA (1) CA1249823A (en, 2012)
CS (1) CS399991A3 (en, 2012)
DE (1) DE3372965D1 (en, 2012)
DK (1) DK322783D0 (en, 2012)
ES (4) ES8601106A1 (en, 2012)
FI (1) FI83770C (en, 2012)
GR (1) GR79232B (en, 2012)
HK (1) HK92690A (en, 2012)
HU (1) HU191296B (en, 2012)
IE (1) IE55941B1 (en, 2012)
IL (1) IL69217A (en, 2012)
LU (1) LU88769I2 (en, 2012)
MX (1) MX9203451A (en, 2012)
NL (1) NL950029I2 (en, 2012)
NO (2) NO164974C (en, 2012)
NZ (1) NZ204995A (en, 2012)
PT (1) PT77087B (en, 2012)
ZA (1) ZA835182B (en, 2012)

Families Citing this family (309)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54115075A (en) * 1978-02-28 1979-09-07 Cho Lsi Gijutsu Kenkyu Kumiai Plasma etching method
FR2540495B1 (fr) * 1983-02-07 1986-02-14 Roussel Uclaf Nouveaux derives de o-mercaptopropanamide et de ses homologues, leur procede de preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US4921941A (en) * 1987-07-01 1990-05-01 Schering Corporation Orally active antiandrogens
US4970303A (en) * 1988-02-03 1990-11-13 Xoma Corporation Linking agents and methods
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
GB9214120D0 (en) * 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
GB9305295D0 (en) * 1993-03-15 1993-05-05 Zeneca Ltd Therapeutic compounds
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
EP0748220A4 (en) * 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
DE4420777A1 (de) 1994-06-15 1995-12-21 Bayer Ag Verfahren zur Herstellung von 4-Fluorthiophenol
AU696788B2 (en) * 1994-06-27 1998-09-17 Neutron Therapies Inc. Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors
US7205437B2 (en) * 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6492554B2 (en) 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20090264534A1 (en) * 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US20050038110A1 (en) * 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
WO1998053826A1 (en) * 1997-05-30 1998-12-03 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
US6019957A (en) * 1997-06-04 2000-02-01 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
DE19746512A1 (de) 1997-10-22 1999-04-29 Bayer Ag Verfahren zur Herstellung von Arylmercaptanen durch Hydrierung von Diaryldisulfiden
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
JP2003525856A (ja) * 1998-08-28 2003-09-02 スミスクライン・ビーチャム・コーポレイション ２−アミノ−５−シアノフェノールの製法
US6184249B1 (en) 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6472415B1 (en) * 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
HU223950B1 (hu) * 1999-06-10 2005-03-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás a racém, valamint az R-(-)- és S-(+)-N-[4-ciano-3-(trifluor-metil)-fenil]-3-[(4-fluor-fenil)-szulfonil]-2-hidroxi-2-metil-propánsavamid előállítására
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
HUP0202725A3 (en) 1999-09-04 2005-04-28 Astrazeneca Ab Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity, process for their preparation and pharmaceutical compositions containing them
EP1214295B1 (en) 1999-09-04 2006-11-02 AstraZeneca AB Hydroxyacetamidobenzenesulphonamide derivatives
DE60039359D1 (de) 1999-09-04 2008-08-14 Astrazeneca Ab Amide als pyruvatdehydrogenaseinhibitoren
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
PL354620A1 (en) 1999-10-19 2004-02-09 Nobex Corporation Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
IL149256A0 (en) * 1999-10-27 2002-11-10 Nobex Corp Resolution of intermediates in the synthesis of substantially pure bicalutamide
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
GB0012293D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6828458B2 (en) 2000-05-25 2004-12-07 Biophysica, Inc. Topical antiandrogen for hair loss and other hyperandrogenic conditions
GB0016426D0 (en) * 2000-07-05 2000-08-23 Astrazeneca Ab Pharmaceutical combination
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20070173546A1 (en) * 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
JP2004518617A (ja) * 2000-08-24 2004-06-24 ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレーション 選択的アンドロゲン受容体モジュレーター及びその使用方法
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US20030232792A1 (en) * 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8008348B2 (en) 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US6562994B2 (en) * 2000-09-21 2003-05-13 Bristol-Myers Squibb Co. Process for the preparation of N-(substituted phenyl)-3-alkyl-,aryl- and heteroarylsulfonyl-2-hydroxy-2-alkyl- and haloalkylpropanamide compounds
EP2269603B1 (en) 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
RU2003128971A (ru) * 2001-02-27 2005-03-10 Астразенека Аб (Se) Фармацевтический препарат
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
DK1392313T3 (da) 2001-05-16 2007-06-25 Novartis Ag Kombination omfattende N-{5-[4-(4-methyl-piperazino-methyl)-benzoyl-amido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidin-amin og et biphosphonat
EP1406855A4 (en) 2001-06-13 2006-04-19 Teva Gyogyszergyar Reszvenytar NOVEL PROCESS FOR THE PREPARATION OF RAC-BICALUTAMIDE AND INTERMEDIATE PRODUCTS THEREOF
US7102026B2 (en) * 2001-06-13 2006-09-05 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for preparing and isolating rac-bicalutamide and its intermediates
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
AU2002322493A1 (en) * 2001-07-10 2003-01-29 Ams Research Corporation Surgical kit for treating prostate tissue
US20060004042A1 (en) * 2001-08-23 2006-01-05 Dalton James T Formulations comprising selective androgen receptor modulators
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
AT410545B (de) * 2001-11-07 2003-05-26 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von chiralen alpha-hydroxycarbonsäuren
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
DK1463497T3 (da) * 2001-12-06 2012-01-30 Gtx Inc Behandling af muskelsvind med selektive androgenreceptormodulatorer
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
EP1462442B1 (en) * 2001-12-13 2009-08-26 Sumitomo Chemical Company, Limited Crystals of bicalutamide and process for their production
CA2689080C (en) * 2002-02-07 2011-07-05 University Of Tennessee Research Foundation Treating benign prostate hyperplasia with sarms
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
CN1639110A (zh) * 2002-02-28 2005-07-13 田纳西大学研究基金会 卤代乙酰胺和叠氮化物取代的化合物及其使用方法
ATE533494T1 (de) * 2002-02-28 2011-12-15 Univ Tennessee Res Foundation Mehrfach substituierte selektive androgen- rezeptor-modulatoren und anwendungsverfahren dafür
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
MXPA04011384A (es) 2002-05-16 2005-02-14 Novartis Ag Uso de agentes de union del receptor edg en cancer.
US7741371B2 (en) 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
JP2005529952A (ja) 2002-06-17 2005-10-06 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション Ｎ架橋選択的アンドロゲン受容体修飾物質及びその使用方法
AU2003248052A1 (en) 2002-07-12 2004-02-02 Yamanouchi Pharmaceutical Co., Ltd. N-phenyl-(2r,5s)dimethylpiperadine derivative
US20040063782A1 (en) * 2002-09-27 2004-04-01 Westheim Raymond J.H. Bicalutamide forms
US6818766B2 (en) * 2002-10-02 2004-11-16 Synthon Bv Process for making bicalutamide and intermediates thereof
EP1562906A4 (en) * 2002-10-15 2009-12-02 Univ Tennessee Res Foundation HETEROCYCLIC SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHOD FOR THEIR USE
CA2501797A1 (en) * 2002-10-15 2004-04-29 Gtx, Inc. Treating obesity with selective androgen receptor modulators
US20040197928A1 (en) * 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
JP2006506369A (ja) * 2002-10-15 2006-02-23 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション メチレン架橋選択的アンドロゲン受容体調節剤及びその使用方法
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
JP2006505564A (ja) * 2002-10-16 2006-02-16 ジーティーエックス・インコーポレイテッド Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療
US20040087810A1 (en) * 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
PL201540B1 (pl) * 2002-10-30 2009-04-30 Inst Farmaceutyczny Sposób wytwarzania wysokiej czystości N-(4-cyjano-3-trifluorometylofenylo)-3-(4-fluorofenylosulfonylo)-2-hydroksy-2-metylopropanamidu
PL201541B1 (pl) * 2002-10-30 2009-04-30 Inst Farmaceutyczny Sposób wytwarzania N-(4-cyjano-3-trifluorometylofenylo)-2,3-epoksy-2-metylopropanamidu
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
DK1592658T3 (da) 2003-01-13 2013-07-29 Univ Tennessee Res Foundation Syntese af selektive, androgene receptormodulatorer i stor målestok
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20050020675A1 (en) * 2003-02-21 2005-01-27 Parthasaradhi Reddy Bandi Bicalutamide polymorphs
US20040167103A1 (en) * 2003-02-24 2004-08-26 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
EP1596857B1 (en) 2003-02-27 2008-10-29 Wisconsin Alumni Research Foundation Pmcol for the treatment of prostate cancer
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
AU2003247740A1 (en) * 2003-06-25 2005-02-14 Teva Gyogyszergyar Reszventarsasag Process for purifying and isolating rac-bicalutamide
CN100462353C (zh) * 2003-06-27 2009-02-18 奥赖恩公司 用作雄激素受体调节剂的丙酰胺衍生物
DE602004026583D1 (de) * 2003-06-27 2010-05-27 Orion Corp Als androgenrezeptormodulatoren geeignete propionamidderivate
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
MXPA06000794A (es) 2003-07-22 2006-08-23 Astex Therapeutics Ltd Compuestos 1h-pirazola 3,4-disustituida y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicogeno (gsr-3).
JP2005060302A (ja) * 2003-08-12 2005-03-10 Sumitomo Chemical Co Ltd Ｎ−メタクリロイル−４−シアノ−３−トリフルオロメチルアニリンの製造方法および安定化方法
CN1838956A (zh) 2003-08-22 2006-09-27 配体药物公司 作为雄激素受体调节剂化合物的6－环氨基－2－喹啉酮衍生物
AU2004281708B2 (en) * 2003-10-14 2011-02-17 University Of Tennessee Research Foundation Treating bone-related disorders with selective androgen receptor modulators
TW200523235A (en) * 2003-10-15 2005-07-16 Gtx Inc Anti-cancer compounds and methods of use thereof
RU2422450C2 (ru) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
AU2004305061A1 (en) 2003-12-16 2005-07-07 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
US20050250709A1 (en) * 2003-12-19 2005-11-10 Bionaut Pharmaceuticals Anti-neoplastic agents, combination therapies and related methods
BRPI0507670A (pt) 2004-02-13 2007-07-17 Warner Lambert Co moduladores do receptor de androgênio
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
KR20080083220A (ko) 2004-04-07 2008-09-16 노파르티스 아게 Ｉａｐ 억제제
BRPI0509759A (pt) 2004-04-13 2007-10-16 Warner Lambert Co moduladores de androgênio
EP1740533A1 (en) 2004-04-22 2007-01-10 Warner-Lambert Company LLC Androgen modulators
EA011306B8 (ru) * 2004-06-07 2012-10-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Избирательные модуляторы андрогеновых рецепторов и способы их применения
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
ITMI20041222A1 (it) 2004-06-17 2004-09-17 Cosma S P A Procedimento perfezionato per la sintesi di bicalutamide
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1781598A1 (en) 2004-07-08 2007-05-09 Warner-Lambert Company LLC Androgen modulators
NZ552392A (en) 2004-07-14 2010-02-26 Sumitomo Chemical Co Method of crystallizing bicalutamide
US20060258628A1 (en) * 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
US20060135468A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
WO2006028969A1 (en) * 2004-09-02 2006-03-16 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using na+/k+ atpase inhibitors
US20070105790A1 (en) * 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
US20060135441A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors
US20080027010A1 (en) * 2004-09-02 2008-01-31 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using Na+/K+-ATPase inhibitors
EP1812010A2 (en) * 2004-10-18 2007-08-01 BTG International Limited Use of na+/ k+-atpase inhibitors and antagonists thereof
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
RU2436575C2 (ru) * 2005-01-21 2011-12-20 Астекс Терапьютикс Лимитед Соединения для использования в фармацевтике
EP1863759A1 (en) * 2005-03-29 2007-12-12 Usv Limited Process for preparation of bicalutamide
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
NZ560354A (en) * 2005-06-17 2010-10-29 Ligand Pharm Inc Androgen receptor modulator compounds and methods
CA2513356A1 (en) * 2005-07-26 2007-01-26 Apotex Pharmachem Inc. Process for production of bicalutamide
CA2623034A1 (en) 2005-09-27 2007-04-05 Novartis Ag Carboxyamine compounds and their use in the treatment of hdac dependent diseases
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
PT2275103E (pt) 2005-11-21 2014-07-24 Novartis Ag Inibidores de mtor para o tratamento de tumores endócrinos
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AU2006329551A1 (en) * 2005-12-27 2007-07-05 Dabur Pharma Limited An improved process for preparation of Bicalutamide
JP5373405B2 (ja) * 2006-03-03 2013-12-18 オリオン コーポレーション 選択的アンドロゲン受容体モジュレーター
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
MX2008012492A (es) 2006-03-29 2008-12-12 Univ California Compuestos de diariltiohidantoina.
EP2591775A1 (en) 2006-04-05 2013-05-15 Novartis AG Combinations comprising mtor inhibitors for treating cancer
EP2314297A1 (en) 2006-04-05 2011-04-27 Novartis AG Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
AR078793A1 (es) 2006-04-07 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
AU2007247112B2 (en) 2006-05-09 2010-08-26 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
WO2008013791A2 (en) * 2006-07-24 2008-01-31 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
PT2054049E (pt) 2006-08-24 2016-06-02 Univ Tennessee Res Found Acilanilidas substituídas e métodos de utilização das mesmas
CN101516885A (zh) 2006-09-29 2009-08-26 诺瓦提斯公司 作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物
WO2008044033A1 (en) * 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
EP4566557A3 (en) 2007-01-02 2025-08-27 AquaBeam LLC Minimally invasive devices for the treatment of prostate diseases
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
US12290277B2 (en) 2007-01-02 2025-05-06 Aquabeam, Llc Tissue resection with pressure sensing
WO2008100985A2 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US8110550B2 (en) 2007-06-06 2012-02-07 University Of Maryland, Baltimore HDAC inhibitors and hormone targeted drugs for the treatment of cancer
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US20090076158A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched bicalutamide
EP2220050A2 (en) 2007-10-26 2010-08-25 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
ES2769535T3 (es) 2008-03-06 2020-06-26 Aquabeam Llc Ablación de tejido y cauterización con energía óptica transportada en una corriente de fluido
KR101673621B1 (ko) 2008-03-24 2016-11-07 노파르티스 아게 아릴술폰아미드-계 매트릭스 메탈로프로테아제 억제제
MY150437A (en) 2008-03-26 2014-01-30 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
WO2014127242A2 (en) 2013-02-14 2014-08-21 Procept Biorobotics Corporation Aquablation aquabeam eye surgery methods and apparatus
US8741951B2 (en) 2009-04-10 2014-06-03 CNR—Consiglio Nazionale Delle Ricerche Non-steroidal compounds for androgen receptor modulation
ITBO20090235A1 (it) * 2009-04-10 2010-10-11 Consiglio Nazionale Ricerche Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi
KR101360725B1 (ko) 2009-06-26 2014-02-07 노파르티스 아게 Ｃｙｐ17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
US8450374B2 (en) * 2009-06-29 2013-05-28 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
US8497368B2 (en) 2009-08-12 2013-07-30 Novartis Ag Heterocyclic hydrazone compounds
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
CN102574785A (zh) 2009-08-26 2012-07-11 诺瓦提斯公司 四取代的杂芳基化合物和它们作为mdm2和/或mdm4调节剂的用途
WO2011029915A1 (en) 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls
EP2496575B1 (en) 2009-11-04 2014-04-30 Novartis AG Heterocyclic sulfonamide derivatives useful as mek inhibitors
US20120289501A1 (en) 2009-11-25 2012-11-15 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
WO2011064663A1 (en) 2009-11-25 2011-06-03 Festuccia, Claudio Combination treatment employing belinostat and bicalutamide
AU2012265844A1 (en) 2009-12-08 2013-05-02 Novartis Ag Heterocyclic sulfonamide derivatives
BR112012013735A2 (pt) 2009-12-08 2019-09-24 Novartis Ag derivados heterocícilicos de sulfonamida
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
CN101759597B (zh) * 2009-12-31 2013-09-04 上海康鹏化学有限公司 2-三氟甲基-4-氨基苯腈的制备方法
JP2013516501A (ja) * 2010-01-11 2013-05-13 ジーティーエックス・インコーポレイテッド マイボーム腺機能障害を治療する方法
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
FI20105806A0 (fi) 2010-07-15 2010-07-15 Medeia Therapeutics Ltd Uudet aryyliamidijohdannaiset, joilla on antiandrogeenisia ominaisuuksia
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
WO2012042532A1 (en) 2010-09-29 2012-04-05 Shilpa Medicare Limited Process for preparing bicalutamide
EP2672958A1 (en) 2011-02-08 2013-12-18 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP2014507465A (ja) 2011-03-08 2014-03-27 ノバルティス アーゲー フルオロフェニル二環式ヘテロアリール化合物
EA024245B1 (ru) 2011-04-21 2016-08-31 Орион Корпорейшн Карбоксамиды, модулирующие андрогенные рецепторы
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
WO2012158707A1 (en) 2011-05-16 2012-11-22 Genzyme Corporation Use of cxcr4 antagonists
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
MX2013015001A (es) 2011-06-27 2014-03-31 Novartis Ag Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a.
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
EP2785717B1 (en) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidine compounds
HRP20191982T4 (hr) 2011-11-30 2023-01-06 Astrazeneca Ab Kombinacijsko liječenje raka
EP2794594A1 (en) 2011-12-22 2014-10-29 Novartis AG Quinoline derivatives
MA37142B1 (fr) 2011-12-22 2019-07-31 Novartis Ag Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
JP2015503518A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
JP2015503516A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
US20140357666A1 (en) 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
MX356499B (es) 2012-01-13 2018-05-30 Medeia Therapeutics Ltd Derivados de heteroarilamida novedosos que tienen propiedades antiandrogénicas.
AR089701A1 (es) 2012-01-13 2014-09-10 Medeia Therapeutics Ltd Derivados de arilamida que tienen propiedades antiandrogenicas
AR089703A1 (es) 2012-01-13 2014-09-10 Medeia Therapeutics Ltd Derivados de arilamida que tienen propiedades antiandrogenicas
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
EP3351196A1 (en) 2012-02-29 2018-07-25 Procept Biorobotics Corporation Automated image-guided tissue resection and treatment
EP2834246B1 (en) 2012-04-03 2021-07-28 Novartis AG Combination products with tyrosine kinase inhibitors and their use
WO2013152170A1 (en) 2012-04-04 2013-10-10 Catylix, Inc. Selective androgen receptor modulators
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
US20130310387A1 (en) 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
HRP20201463T1 (hr) 2012-07-13 2021-04-02 Oncternal Therapeutics, Inc. Postupak liječenja raka dojke selektivnim modulatorom androgenskog receptora (sarm)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
EP2882747B1 (en) 2012-08-13 2016-04-27 Novartis AG Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (syk)
WO2014053491A1 (en) 2012-10-02 2014-04-10 Epitherapeutics Aps Inhibitors of histone demethylases
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
RU2510392C1 (ru) * 2012-12-21 2014-03-27 Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) Сокристаллическая форма бикалутамида
EP2948451B1 (en) 2013-01-22 2017-07-12 Novartis AG Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
JP6514117B2 (ja) 2013-02-27 2019-05-15 エピセラピューティクス アーペーエス ヒストン脱メチル化酵素の阻害剤
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
JP6461971B2 (ja) 2013-09-06 2019-01-30 プロセプト バイオロボティクス コーポレイション 飛散パルスを用いた組織切除および処置
AU2014321420B2 (en) 2013-09-22 2017-06-15 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103772238B (zh) * 2014-01-24 2017-03-22 苏州伊莱特新药研发有限公司 一类新的含酯基芳香丙酰胺化合物及其制备方法和用途
US9394281B2 (en) 2014-03-28 2016-07-19 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
JP2017512804A (ja) 2014-03-31 2017-05-25 ギリアード サイエンシーズ， インコーポレイテッド ヒストン脱メチル化酵素の阻害剤
WO2015196144A2 (en) 2014-06-20 2015-12-23 England Pamela M Androgen receptor antagonists
CN106572864B (zh) 2014-06-30 2020-06-09 普罗赛普特生物机器人公司 流体射流组织切除和寒凝装置
CN104151197B (zh) * 2014-07-25 2017-02-22 苏州伊莱特新药研发有限公司 芳香丙酰胺类化合物及其制备方法和应用
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
AR101692A1 (es) 2014-08-27 2017-01-04 Epitherapeutics Aps Compuestos y métodos para inhibir histonas demetilasas
EP4477143A3 (en) 2014-09-05 2025-03-19 PROCEPT BioRobotics Corporation Physician controlled tissue resection integrated with treatment mapping of target organ images
WO2016079522A1 (en) 2014-11-20 2016-05-26 University College Cardiff Consultants Limited Androgen receptor modulators and their use as anti-cancer agents
WO2016079521A1 (en) 2014-11-20 2016-05-26 University College Cardiff Consultants Limited Androgen receptor modulators and their use as anti-cancer agents
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CA2983426C (en) 2015-04-21 2023-10-17 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
MX2017013563A (es) 2015-04-21 2018-07-06 Gtx Inc LIGANDOS DEGRADADORES SELECTIVOS DEL RECEPTOR ANDROGí‰NICO (SARD) Y SUS Mí‰TODOS DE USO.
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CN106748884B (zh) * 2016-12-13 2021-08-20 山西振东制药股份有限公司 一种比卡鲁胺中间体的制备方法
WO2019099311A1 (en) 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
US11602534B2 (en) 2017-12-21 2023-03-14 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Pyrimidine derivative kinase inhibitors
KR102737185B1 (ko) 2018-01-20 2024-12-05 선샤인 레이크 파르마 컴퍼니 리미티드 치환된 아미노피리미딘 화합물 및 이의 사용 방법
WO2020051344A1 (en) 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
JP2022509917A (ja) 2018-11-05 2022-01-25 ファイザー・インク がんを処置するための組合せ
CN109438297B (zh) * 2018-12-03 2021-05-14 昆明积大制药股份有限公司 雄激素受体拮抗剂、其制备方法及其应用
KR20220003554A (ko) 2019-04-19 2022-01-10 리간드 파마슈티칼스 인코포레이티드 화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
MX2021013774A (es) 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
MX2023001823A (es) 2020-08-13 2023-03-13 Pfizer Terapia de combinacion.
KR20230159510A (ko) 2021-03-24 2023-11-21 화이자 인코포레이티드 Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
WO2025045058A1 (zh) * 2023-08-28 2025-03-06 中国药科大学 作为雄激素受体拮抗剂的化合物
WO2025067483A1 (zh) * 2023-09-28 2025-04-03 中国药科大学 酰胺类化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133119A (en) * 1961-11-09 1964-05-12 Givaudan Corp Substituted acetanilides and propionanilides
US3995060A (en) * 1972-06-20 1976-11-30 Schering Corporation Antiandrogenic agents and method for the treatment of androgen dependent disease states
CH493198A (de) * 1968-05-06 1970-07-15 Ciba Geigy Schädlingsbekämpfungsmittel
FR2142803A1 (en) * 1971-06-25 1973-02-02 Scherico Ltd 3,4-disubstd anilides - having antiandrogenic activity
US3875229A (en) * 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
US4144270A (en) * 1973-04-19 1979-03-13 Schering Corporation Substituted anilides as anti-androgens
US4329364A (en) * 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4039684A (en) * 1976-03-25 1977-08-02 Schering Corporation Method for treatment of canine seborrhea
JPS6044294B2 (ja) * 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
EP0002309B1 (en) * 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) * 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) * 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
ES8607915A1 (es) 1986-06-01
FI83770C (fi) 1991-08-26
ES524392A0 (es) 1985-11-01
FI832644A0 (fi) 1983-07-20
AU556328B2 (en) 1986-10-30
LU88769I2 (fr) 1996-11-05
GR79232B (en, 2012) 1984-10-22
ES8700231A1 (es) 1986-09-16
IL69217A0 (en) 1983-11-30
IL69217A (en) 1987-03-31
ES539614A0 (es) 1986-06-01
NO1996014I1 (no) 1996-12-10
US4636505A (en) 1987-01-13
ES8601106A1 (es) 1985-11-01
JPH02131462A (ja) 1990-05-21
NO164974B (no) 1990-08-27
IE831732L (en) 1984-01-23
NL950029I1 (en, 2012) 1996-02-01
DK322783D0 (da) 1983-07-13
EP0100172A1 (en) 1984-02-08
CS399991A3 (en) 1992-06-17
PT77087A (en) 1983-08-01
NZ204995A (en) 1985-08-30
FI83770B (fi) 1991-05-15
CA1249823A (en) 1989-02-07
HK92690A (en) 1990-11-16
AU1693783A (en) 1984-01-26
JPS5933250A (ja) 1984-02-23
ZA835182B (en) 1984-05-30
ES544189A0 (es) 1986-09-16
HU191296B (en) 1987-02-27
ATE28864T1 (de) 1987-08-15
NO832599L (no) 1984-01-24
NO164974C (no) 1990-12-05
EP0100172B1 (en) 1987-08-12
PT77087B (en) 1986-01-27
DE3372965D1 (en) 1987-09-17
ES8607936A1 (es) 1986-06-01
NL950029I2 (nl) 1997-03-03
MX9203451A (es) 1992-08-01
ES539615A0 (es) 1986-06-01
IE55941B1 (en) 1991-02-27
FI832644A7 (fi) 1984-01-24

Similar Documents

Publication Publication Date Title
JPH0432061B2 (en, 2012)
EP0253503B1 (en) Substituted anilides having antiandrogenic properties
JP3894949B2 (ja) 抗アテローム性動脈硬化症ジアリール化合物
US4386080A (en) Anti-androgenic amide derivative
DE69522676T2 (de) Naphtalen-derivate als prostaglandin i2 agonisten
EP1230244B1 (fr) Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
JP3067809B2 (ja) 新規置換２，４―チアゾリジンジオン誘導体、その製造方法およびそれを含む薬剤組成物
EA001472B1 (ru) Кристаллическая форма 4-[5-метил-3-фенилизоксазол-4-ил]бензолсульфонамида
JPH11500748A (ja) Ｃｏｘ−２阻害剤のプロドラッグとしての３，４−ジアリール−２−ヒドロキシ−２，５−ジヒドロフラン
KR100513302B1 (ko) 3-아미노-1,2-벤조이소옥사졸 유도체, 이의 제조방법및 용도
JPS61189243A (ja) アルケン誘導体およびその製法
JPS6097924A (ja) 抗炎症剤として有用な置換シンナミル‐２，３‐ジヒドロベンゾフランおよび類似体
JPH06329617A (ja) 治療用化合物
JPH0379336B2 (en, 2012)
JP2000505421A (ja) Ｃｏｘ―２阻害剤のプロドラッグとしてのアルキル化スチレン
FR2467199A1 (fr) Nouveaux composes heterocycliques azotes anti-inflammatoires et immunoregulateurs et composition pharmaceutique les contenant
FR2582654A1 (fr) Steroides 11b-substitues utiles notamment dans le traitement des tumeurs hormono-dependantes et procede pour la fabrication
US5464865A (en) 4-aryl- and 4-arylthio-5-hydroxy-2(5H)-furanones as inhibitors of phospholipase A2
EP0184809B1 (en) Imidazolylalkoxyindanic derivatives, a process for preparing them and pharmaceutical composition containing them
JPH02124869A (ja) ロイコトリエン拮抗剤のエステルプロドラッグ
JP2885901B2 (ja) ジアリールエーテルシクロアルカン、その製造方法、これを含有する酵素５−リポキシゲナーゼの阻害剤
CZ218794A3 (en) Quinoline compounds, process of their preparation and pharmaceutical compositions containing thereof
HU180103B (en) Process for producing analogues of 9,11,15-trideoxy-prostaglandine-f
WO2012104538A1 (fr) Nouveaux dérivés de 1, 5 - dihydropyrrol - 2 - one utiles pour le traitement paludisme ou d'autres maladies parasitaires et fongiques
JPH05345768A (ja) 新規トリアゾール化合物及び該化合物を有効成分とする抗真菌剤

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090528

Year of fee payment: 17